You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • AB0484 An Integrated Pharmacokinetic and Pharmacodynamic Approach to Guide Dose Selection of Namilumab, an Anti-GM-CSF Monoclonal Antibody, for Phase II Rheumatoid Arthritis Studies

Article metrics

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Rheumatoid arthritis - other biologic treatment
AB0484 An Integrated Pharmacokinetic and Pharmacodynamic Approach to Guide Dose Selection of Namilumab, an Anti-GM-CSF Monoclonal Antibody, for Phase II Rheumatoid Arthritis Studies

 

Online download statistics by month:

Online download statistics by month: June 2015 to March 2024

AbstractFullPdf
Jun 20151801
Jul 20151201
Aug 2015300
Sep 2015802
Oct 2015300
Nov 2015401
Dec 20151003
Jan 2016801
Feb 2016100
Mar 20161002
Apr 2016500
May 2016900
Jun 20161103
Jul 2016900
Aug 2016200
Sep 2016502
Oct 20161501
Nov 20161905
Dec 2016601
Jan 2017301
Feb 2017401
Mar 2017600
Apr 2017800
May 2017900
Jun 2017601
Jul 20171202
Aug 20171200
Sep 20171601
Oct 20171000
Nov 20172201
Dec 2017600
Jan 2018400
Feb 20184401
Mar 20182401
Apr 20181600
May 20184800
Jun 20181200
Jul 20181800
Aug 20181400
Oct 2018600
Nov 20181400
Dec 2018800
Jan 2019400
Feb 2019200
Mar 2019300
Apr 2019700
May 2019800
Jun 2019101
Jul 20191800
Aug 20194200
Sep 20191000
Nov 2019200
Dec 2019600
Jan 2020301
Feb 2020100
Apr 2020600
May 2020600
Jun 2020700
Jul 2020800
Aug 2020400
Sep 20201700
Oct 2020500
Nov 2020800
Dec 2020300
Jan 2021400
Feb 2021200
Apr 2021100
Jun 2021500
Sep 2021101
Oct 2021500
Nov 20211400
Dec 2021700
Feb 2022200
Mar 20223800
Apr 2022600
May 20221400
Jun 20222001
Jul 20222401
Aug 20222000
Sep 2022500
Oct 2022800
Nov 20221600
Dec 20221200
Jan 2023900
Feb 2023600
Mar 2023700
Apr 2023500
May 2023700
Jun 2023801
Jul 20231100
Aug 2023400
Sep 2023800
Nov 2023100
Dec 20231701
Jan 20241201
Feb 2024900
Mar 20241200
Total971040